Michael Levy

Selecting treatment options for NMOSD 1:51
Selecting treatment options for NMOSD
Michael Levy • 3 Apr 2022
Challenges in the differential diagnosis of NMOSD from MS 1:38
Challenges in the differential diagnosis of NMOSD from MS
Michael Levy • 3 Apr 2022
Updates in epidemiology data in NMOSD 2:00
Updates in epidemiology data in NMOSD
Michael Levy • 3 Apr 2022
Research developments in MOGAD 1:23
Research developments in MOGAD
Michael Levy • 25 Feb 2022
SAkura: long-term safety and efficacy of satralizumab for NMOSD 1:27
SAkura: long-term safety and efficacy of satralizumab for NMOSD
Michael Levy • 25 Feb 2022
Recent progress and future needs in NMOSD treatment 1:39
Recent progress and future needs in NMOSD treatment
Michael Levy • 25 Feb 2022
Investigating subcutaneous immunoglobulin therapy in MOGAD 1:25
Investigating subcutaneous immunoglobulin therapy in MOGAD
Michael Levy • 25 Feb 2022
SPHERES: collecting real-world data to explore disease characteristics & clinical outcomes in NMOSD 10:36
SPHERES: collecting real-world data to explore disease characteristics & clinical outcomes in NMOSD
Brian Weinshenker et al. • 28 Feb 2022
cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGAD 1:32
cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGAD
Michael Levy • 25 Feb 2022
The content of VJNeurology is intended for healthcare professionals